慢性移植物抗宿主病初始治疗后与临床获益相关的终点
在328例新诊断慢性GVHD患者的前瞻性多中心观察研究中,按2014年NIH共识标准定义疗效,1年时完全或部分缓解且未接受二线系统治疗或恶性肿瘤复发者不足20%;该组1年疾病负担低于稳定或进展组,系统治疗结束更早且后续死亡率更低。
要点
- 1年时完全或部分缓解且无二线系统治疗或恶性肿瘤复发者不足20%。
- 该组1年疾病表现负担低于稳定或进展性疾病组。
- 该组系统治疗结束更早,后续死亡率低于稳定或进展组及接受二线系统治疗者。
核心结论
- 初始系统治疗后1年时完全或部分缓解且未接受过二线系统治疗或恶性肿瘤复发,与临床获益相关,是作为关键临床试验主要终点需考虑的关键特征。
研究设计与样本
- 前瞻性、多中心、观察性研究,纳入慢性GVHD诊断后3个月内的328例患者,注册号NCT00637689。
主要发现
- 成功(1年时完全或部分缓解且无二线系统治疗或恶性肿瘤复发)见于不足20%的患者。
- 1年时疾病表现负担:成功组低于稳定或进展性疾病组。
- 系统治疗结束时间:完全或部分缓解组早于稳定或进展性疾病组及接受二线系统治疗者。
- 后续死亡率:完全或部分缓解组低于稳定或进展性疾病组及接受二线系统治疗者。
关键数值与推荐
- 完全缓解、部分缓解、稳定疾病和进展性疾病按2014年美国国立卫生研究院慢性GVHD临床试验标准共识会议定义。
- 成功定义为入组后1年时完全或部分缓解且无二线系统治疗或恶性肿瘤复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
No gold standard has been established as a primary endpoint in trials of initial treatment of chronic graft-versus-host disease (GVHD), and evidence showing the association of any proposed primary endpoint with clinical benefit has not been conclusively demonstrated. To address this gap, we analyzed outcomes in a cohort of 328 patients enrolled in a prospective, multicenter, observational study within 3 months after diagnosis of chronic GVHD. Complete and partial response, stable disease, and progressive disease were defined according to the 2014 National Institutes of Health Consensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Success was defined as complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment. Success was observed in fewer than 20% of the patients. The burden of disease manifestations at 1 year was lower for patients in this category than for those with stable or progressive disease. Systemic treatment ended earlier, and subsequent mortality was lower among patients with complete or partial response than among those with stable or progressive disease and those who had received secondary systemic treatment. We conclude that survival with a complete or partial response and no previous secondary systemic treatment or recurrent malignancy at 1 year after initial systemic therapy is associated with clinical benefit, a critical characteristic for consideration as a primary endpoint in a pivotal clinical trial. This prospective observational study was registered at www.clinicaltrials.gov as #NCT00637689.
引用
- Martin PJ, Storer BE, Inamoto Y, et al. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood. 2017. PMID: 28495794. doi:10.1182/blood-2017-03-775767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。